May 20, 2025
TOPLINE: Biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) seemed to be the most effective treatments for patients with acute psoriatic arthritis (PsA) dactylitis. METHODOLOGY: In […]
May 20, 2025
TOPLINE: Patients with psoriatic arthritis (PsA) who were left-handed had increased peripheral damage on radiographic assessment, particularly in the hands, with a greater impact observed on […]
May 19, 2025
TORONTO — Older patients with axial spondyloarthritis (axSpA) are known to have a higher overall risk for cancer than the general population, but new evidence from […]
May 19, 2025
TOPLINE: Patients with axial spondyloarthritis (axSpA) and moderate to severe depressive symptoms were less likely to achieve low disease activity (LDA) and inactive disease following the […]
May 19, 2025
TOPLINE: Zimlovisertib plus tofacitinib showed greater efficacy than tofacitinib alone in reducing Disease Activity Score in 28 joints using C-reactive protein (DAS28-CRP) in patients with rheumatoid […]
May 16, 2025
MANCHESTER, England — The risks for infection are broadly similar regardless of the biologic or targeted synthetic disease-modifying drug used to treat inflammatory arthritis, but different […]
May 15, 2025
INCHEON, South Korea — Young veterans who have lost lower limbs in combat are at particularly high risk for developing hip osteoarthritis, but even uninjured veterans […]
May 14, 2025
TORONTO — After almost 10 years, the much-anticipated revision of the current classification criteria for the diagnosis of axial spondyloarthritis (axSpA) is ready for prime time. […]
May 14, 2025
TOPLINE: In patients with systemic lupus erythematosus (SLE) who had been in remission for at least 1 year, immunosuppressant withdrawal was noninferior to glucocorticoid withdrawal, with […]